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Summary
Overweight and obesity affect ~1.5 billion people worldwide, and are major risk factors for type-2 
diabetes (T2D), cardiovascular disease and related metabolic and inflammatory disturbances.1,2 
Although the mechanisms linking adiposity to its clinical sequelae are poorly understood, recent 
studies suggest that adiposity may influence DNA methylation,3–6 a key regulator of gene 
expression and molecular phenotype.7 Here we use epigenome-wide association to show that body 
mass index (BMI, a key measure of adiposity) is associated with widespread changes in DNA 
methylation (187 genetic loci at P<1x10-7, range P=9.2x10-8 to 6.0x10-46; N=10,261 samples). 
Genetic association analyses demonstrate that the alterations in DNA methylation are 
predominantly the consequence of adiposity, rather than the cause. We find the methylation loci 
are enriched for functional genomic features in multiple tissues (P<0.05), and show that sentinel 
methylation markers identify gene expression signatures at 38 loci (P<9.0x10-6, range P=5.5x10-6 
to 6.1x10-35, N=1,785 samples). The methylation loci identified highlight genes involved in lipid 
and lipoprotein metabolism, substrate transport, and inflammatory pathways. Finally, we show that 
the disturbances in DNA methylation predict future type-2 diabetes (relative risk per 1SD increase 
in Methylation Risk Score: 2.3 [2.07-2.56]; P=1.1x10-54). Our results provide new insights into the 
biologic pathways influenced by adiposity, and may enable development of new strategies for 
prediction and prevention of type-2 diabetes and other adverse clinical consequences of obesity.
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Our study design is summarised in Extended Data Figure 1. We carried out epigenome-wide 
association amongst 5,387 individuals from the EPICOR (N=514), KORA (N=2,193) and 
LOLIPOP (N=2,680) population studies (Supplementary Information Tables 1 and 2, and 
Supplementary Information). We studied individuals of European (EPICOR, KORA) and 
Indian Asian (LOLIPOP) ancestry, both populations known to be at high risk of obesity and 
related metabolic disturbances.2,8 DNA methylation in genomic DNA from blood was 
quantified by Illumina Infinium 450K Human Methylation array. Blood was chosen for the 
analysis as a metabolically active tissue, with a key role in the adverse inflammatory and 
vascular consequences of adiposity, and which is widely used for clinical diagnostic 
purposes.
Epigenome-wide association identified 278 CpG sites associated with BMI at P<1x10-7, 
distributed between 207 genetic loci (Supplementary Information Tables 3 and 4). At each 
locus we identified the sentinel marker (CpG site with lowest P value for association with 
BMI), and carried out replication testing in separate samples of whole blood from European 
and Indian Asian men and women in population-based studies (N=4,874, Supplementary 
Information Table 1). The association of DNA methylation with BMI replicated at 187 of the 
207 markers (associated with BMI at P<0.05 in replication samples with directional 
consistency, and at epigenome-wide significance in combined analysis of discovery and 
replication data, Figure 1, Supplementary Information Table 3). Regional plots for the 187 
identified loci are shown in Supplementary Information Figures 1 and 2. Effect sizes range 
from 6.3±0.9 to 40.2±3.1 kg/m2 change in BMI per unit increase in DNA methylation in 
blood (scale for methylation 0-1, where 1 represents 100% methylation), with little evidence 
for heterogeneity between Europeans and Indian Asians (Supplementary Information Table 
3). At 7 loci the associations between DNA methylation and BMI are stronger amongst 
Indian Asians or Europeans (Heterogeneity P<1.0x10-7) raising the possibility that some 
effects may be population specific.
Sensitivity analyses show that our findings are robust to choice of analytic strategy. The 
associations of DNA methylation in blood with BMI are not explained by population 
stratification caused by DNA sequence variation, or by genetic confounding by SNPs in the 
probe sequence (Supplementary Information Table 5, Supplementary Information Figures 3 
and 4). In addition, to address the possibility of confounding by technical factors, we further 
replicated the associations of DNA methylation in blood with BMI at 4 loci, amongst 990 
Europeans and 1,720 Indian Asians (LOLIPOP study), using pyrosequencing as an 
alternative approach to quantification of methylation (P=1.2x10-7 to 2.1x10-12 for 
association of methylation with BMI, Supplementary Information Table 6).
The 187 identified methylation markers are strongly enriched for CpG sites with 
intermediate levels of methylation, consistent with the presence of mosaicism, ie epigenetic 
heterogeneity, at these loci (P=1.4x10-22 Fisher’s test, Extended Data Figure 2). To better 
understand the underlying cellular events, and exclude changes in cell subset composition as 
the basis for our findings, we carried out replication testing of the sentinel loci in isolated 
white cell subsets (monocytes, neutrophils, CD4+ T cells, and CD8+ T cells, N=60, 
Supplementary Information Table 7). Epigenetic heterogeneity is present at the majority of 
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loci, in each of the cell subsets studied (Extended Data Figure 3 and Supplementary 
Information Table 8). The sentinel markers are enriched for association with adiposity in 
each of the isolated cell subsets (Extended Data Figure 4 and Supplementary Information 
Table 8), and the relationships between methylation and obesity are directionally consistent 
with the discovery epigenome-wide association study at between 130 loci (CD4+, 
P=1.2x10-9, sign test) and 166 loci (neutrophils, P=5.6x10-35, sign test) (Supplementary 
Information Table 9). Furthermore, effect sizes are directionally consistent and of similar 
magnitude between the isolated cell subsets (Extended Data Figure 5). The association of 
DNA methylation with BMI therefore reflects epigenetic heterogeneity at the identified loci, 
is independent of changes in cell subset distribution, and comprises an effect of adiposity on 
methylation that is shared across the cell subsets studied.
To assess the relevance of our observations in blood to other metabolically relevant tissues, 
we first compared methylation levels at the 187 loci in blood, subcutaneous and omental fat, 
liver, muscle, spleen and pancreas.9 Mean methylation levels at the 187 loci correlate 
moderately to strongly between the tissues (R=0.37 to 0.93, P=8.9x10-8 to 1.9x10-82 for the 
21 tissue pairs, Extended Data Figure 6 and Supplementary Information Figure 5), 
supporting the view that methylation levels in blood are related to methylation patterns in 
other tissues at the CpG sites examined.
lnflammatory and hormonal disturbances in the obese adipocyte contribute to the 
development of insulin resistance and other metabolic consequences of adiposity.10 To 
better understand how our findings in blood might reflect processes in adipose tissue, we 
therefore quantified the relationship between DNA methylation and BMI in adipose tissue. 
120 of the CpG sites show directional consistency for association with BMI in both adipose 
tissue and blood (P=1.3x10-4, binomial test), while 91 sites are associated with BMI in 
adipose tissue (P<2.7x10-4, ie P<0.05 after Bonferroni correction for 187 tests, 
Supplementary Information Table 10). The associations of DNA methylation with BMI in 
adipose tissue are also unlikely to be the result of differences in the composition of 
canonical cell-types. First we used Principal Components Analysis (PCA) to assess for 
cryptic structure arising from variation in cell subset composition in the methylation data. 
Including principal components as covariates in regression models did not materially 
influence the association of DNA methylation with BMI in adipose tissue (Supplementary 
Information Figure 6). In separate studies, we quantified DNA methylation in isolated 
adipocytes from subcutaneous adipose tissue collected from morbidly obese 
(BMI>40kg/m2, N=24) and normal weight (N=24) individuals, Despite small sample size, 6 
of the 187 sentinel markers were associated with obesity at P<2.7x10-4 (P<0.05 after 
Bonferroni correction, Supplementary Information Table 11), while 108 markers show 
relationships with obesity that are directionally consistent with those observed in the 
discovery epigenome-wide association study (P=0.04). We separately tested the association 
of our sentinel methylation markers with BMI in samples of liver (N=55), as a further 
metabolically relevant tissue. We find that the 114 of the CpG sites show consistent direction 
of association with BMI compared to findings in blood (P=0.001, sign test, Supplementary 
Information Table 10), thus providing further replication of our findings in liver cells. Our 
findings indicate that many of the relationships between methylation and BMI in blood are 
shared by adipose and liver cells, but also identify effects that are tissue specific.
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Next, we used genetic association and the concept of Mendelian randomisation to investigate 
the potential causal relationships between DNA methylation in blood and BMI.11 We first 
identified SNPs influencing DNA methylation in blood in cis (1Mb, N=4,034 people). We 
then tested whether SNPs that influence methylation in blood also influence BMI, and 
whether the predicted effects of SNPs on BMI via methylation are consistent with the 
directly observed association. We identify a single CpG (cg26663590: NFATC2IP) showing 
evidence from genetic association for a causal role of methylation on BMI (P=9.6x10-7 for 
association of SNP rs11150675 near NFATC2IP with BMI, Figure 2A and Supplementary 
Information Table 12). In keeping with a causal role for methylation at NFATC2IP 
underlying adiposity, baseline levels of methylation at cg26663590 predict weight gain in 
longitudinal population studies (P=0.03, Supplementary Information Table 13). The 
NFATC2IP locus contains the gene encoding SH2B1 which is known to be involved in 
energy and glucose homeostasis and has previously been linked with obesity, including 
through genome-wide association studies.12,13
To investigate whether DNA methylation in blood is the consequence of adiposity, we used a 
weighted genetic risk score (GRS) that combines effects across SNPs known to influence 
BMI (Figure 2B and Supplementary Information Table 14). We observe a strong correlation 
between predicted (through BMI) and observed effects of BMI GRS on methylation 
(R2=0.65; P=4.7x10-44) at the CpG sites evaluated. In particular, GRS is associated with 
DNA methylation at the ABCG1, KLHL18, FTH1P20 loci at P<2.7x10-4 (corresponding to 
P<0.05 after Bonferroni correction for 187 tests). An effect of BMI on ABCG1 methylation 
is consistent with observations that weight loss influences both ABCG1 expression in 
adipose tissue and ABCG1 activity,14,15 and by the close relationship between change in 
BMI and change in methylation during longitudinal follow-up of participants in our 
population studies (Supplementary Information Table 13). Although further studies are 
needed to consider mechanisms, our findings suggest that adiposity determines the 
alterations in methylation at the majority of the identified CpG sites.
We separately used genetic association to test the causal relationships between BMI and 
DNA methylation in adipose tissue. Results further confirm that in adipose tissue, as in 
blood, the differences in methylation observed are primarily the consequence of adiposity 
(R=0.73, P=1.6×10-32; Extended Data Figure 7).
We carried out functional genomic analyses to explore the potential mechanisms linking the 
187 sentinel CpGs sites with adiposity. The CpG sites are strongly enriched in active 
chromatin sites, including at DNase hypersensitivity sites and the activating histone marks 
H3K4me1 and H3K27ac in a wide range of cell lines (P<0.05, Supplementary Information 
Figure 7) suggesting that the adiposity-related methylation changes we identify occur at 
constitutive cis-regulatory regions that operate across tissues. In keeping with a regulatory 
role, DNA methylation at the 187 identified CpG sites is enriched for association with 
expression of cis-genes (500kb) in blood (Supplementary Information Tables 15 and 16, 
Extended Data Figure 8). We find 44 transcripts of 38 annotated genes that are associated 
with DNA methylation at P<9.0x10-6 (ie P<0.05 after Bonferroni correction, Supplementary 
Information Table 16); a ~3-fold enrichment compared to expectations under the null 
hypothesis (P=3.0x10-4, Extended Data Figure 8). In sensitivity analyses, limiting 
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assessment of the relationship between methylation and gene expression to nearest gene, or 
to Illumina annotated gene, identifies five additional loci potentially associated with gene 
expression (Supplementary Information Table 17). The strongest cis-signals observed are for 
cg09315878 with TNFRSF4 transcription (P=7.2x10-86), cg14476101 with PHGDH 
transcription (P=1.0x10-64) and cg09152259 with MAP3K2 transcription (P=1.6x10-67). On 
average a 5% absolute change in methylation was associated with a 7% change in gene 
expression across the 44 transcripts identified (range 1.8% for AKAP to 19% for SPNS3, 
Supplementary Information Table 16). Amongst the 38 methylation-gene expression 
associations observed in blood, 3 replicated in adipose tissue (HOXA5, BBS2, SELM) and 3 
in liver (ANXA1, LGALS3BP, PHGDH) at P<1.3x10-3 (ie P<0.05 after Bonferroni 
correction for 38 tests), all with consistent direction of effect (Supplementary Information 
Table 18), suggesting that the relationships between methylation and gene expression are in 
part shared between blood, adipose and liver tissue.
We prioritised genes as potential candidate genes involved in the association between BMI 
and DNA methylation at the 187 loci based on two criteria: i. Proximity: gene nearest to the 
sentinel methylation marker, and ii. Functional genomics: genes within 500kb of the sentinel 
methylation marker showing association of gene expression with methylation 
(Supplementary Information Table 19). These criteria identified 210 unique genes, many 
with established roles in adipose tissue biology and insulin resistance (eg ABGG1, LPIN1, 
HOXA5, LMNA, CPT1A, SOCS3, SREBF1, PHGDH, Supplementary Information Tables 
19 and 20). Gene-set enrichment analyses show that the 210 candidate genes are enriched 
for genes involved in lipid and lipoprotein metabolism, amino acid and small molecule 
transport, and inflammatory pathways involving NFKB, MAPK, TAK1, IRAK2 and TRAF6 
(Supplementary Information Table 21).
To investigate the potential clinical significance of the DNA methylation changes, we first 
tested the cross-sectional relationship of DNA methylation in blood with fasting glucose, 
insulin, HDL cholesterol, triglycerides, HbA1c and other clinical traits. We find that 879 
methylation-clinical trait pairs tested are significant at P<2.1x10-5 (ie P<0.05 after 
Bonferroni correction for the 2,431 tests performed, Supplementary Information Figure 8, 
Supplementary Information Table 22), consistent with recent studies reporting close 
relationships of DNA methylation with blood lipids and glucose traits.16,17 We again used 
genetic association to investigate the potential causal relationships between DNA 
methylation and the identified clinical traits. SNPs influencing methylation markers in blood 
showed little evidence for association with the respective clinical traits (Extended Data 
Figure 9). In contrast, the predicted effect of GRS on DNA methylation via clinical trait is 
correlated with the directly observed effect of GRS on methylation for HbA1c, HDL 
cholesterol, triglycerides and insulin (P=1x10-3 to P=2x10-14, Extended Data Figure 9). Our 
findings suggest that the methylation changes in blood may in part be a consequence of the 
changes in lipid and glucose metabolism associated with BMI.
Finally we tested whether DNA methylation levels in blood at the 187 sentinel CpG sites 
predict new onset, incident T2D, a major clinical consequence associated with obesity, 
amongst participants of the LOLIPOP study (N=2,664). In single marker tests, 62 of the 187 
methylation markers are associated with incident T2D at P<2.7x10-4 (ie P<0.05 after 
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Bonferroni correction, Supplementary Information Table 23). The strongest association was 
observed for the ABCG1 locus, a gene known to be involved in insulin secretion and 
pancreatic β-cell function.14,15 To integrate information across CpG sites, we calculated a 
weighted Methylation Risk Score (MRS) as the sum of methylation values at each of the 
markers associated with T2D, weighted by marker-specific effect size. MRS is strongly 
predictive of incident T2D (relative risk 2.29 [95% CI 2.06-2.55] per 1SD change in MRS; 
P=4.2x10-52). The association of MRS with incident T2D replicates in Europeans from the 
KORA study (relative risk 2.51 [95% CI 1.49-4.23] per 1SD change in MRS; P=5.7x10-4), 
with no evidence for heterogeneity of effect (P=0.74). MRS predicts T2D beyond traditional 
risk factors including BMI and waist-hip ratio (Supplementary Information Table 24), and in 
particular identifies obese and overweight individuals at high risk of future T2D (relative 
risk for T2D in obese subjects: 7.3 [4.1-12.9], P=8.2x10-12 in the top vs the lowest quartile, 
Figure 4). This risk of T2D associated with DNA methylation markers as we have estimated 
in our study is numerically similar to, or greater than, the estimated risk conferred by 
traditional risk factors including overweight, obesity, central obesity, impaired fasting 
glucose and hyperinsulinaemia (Extended Data Figure 10). Furthermore, DNA methylation 
remains strongly and independently associated with risk of future T2D even after adjustment 
for adiposity and glycaemic measures. In contrast, emergent risk factors such as CRP and 
amino acid concentrations have little evidence for an independent association with T2D. Our 
findings therefore raise the possibility that DNA methylation markers may help identify 
individuals with metabolically unfavourable adiposity who are at increased risk of future 
T2D.
Our large-scale epigenome-wide association study identifies and replicates changes in DNA 
methylation associated with BMI in blood and adipose tissue. The associations of 
methylation with BMI are independent of variation in cell subset composition and replicate 
in both isolated white blood cells and isolated adipocytes. Genetic association in both blood 
and adipose tissue supports the view that the changes in DNA methylation are a 
consequence and not the cause of adiposity, at the majority of the identified CpG sites. The 
presence of epigenetic heterogeneity at the identified loci, even within isolated canonical cell 
subsets, together with a graded relationship between methylation and BMI, suggest 
epigenetic reprogramming within committed cell subsets in response to adiposity, as 
recently described in other tissues.18 In keeping with this the methylation loci are enriched 
for sites of open chromatin in multiple tissues, consistent with the presence of constitutive 
cis-enhancers.
The candidate genes at these loci include genes with annotated roles in lipid metabolism, 
amino acid and small molecule transport, inflammation, as well as metabolic, 
cardiovascular, respiratory and neoplastic disease. For example, TNFRSF4 and MAP3K2 
encode proteins involved in activation of NF-KB,19 while IL5RA is involved in 
development and activation of eosinophil and other immune cells, and is causally linked to 
asthma, eczema and cardiovascular disease.20 ABCG1 is involved in cholesterol and 
phospholipid transport, and regulates insulin secretion.17,21 Our observations thus provide 
insight into the regulatory pathways that may link adiposity to metabolic and cardiovascular 
disease, asthma and a wide range of cancers, although our study is limited in the tissues 
examined, and further studies are needed to include additional biologically relevant tissues. 
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Our prospective population studies show that DNA methylation identifies people at high risk 
of incident T2D, independent of conventional risk factors. Further studies are needed to 
examine whether DNA methylation markers may be useful in distinguishing metabolically 
unhealthy obesity. This may prove useful in risk stratification and personalized medicine, to 
help tackle the current global epidemic of obesity and its associated cardiovascular and 
metabolic disturbances.
Online Methods
Population samples
Details of the population samples for discovery and replication are provided in the 
Supplementary Information.
Quantification of DNA methylation
Quantification of DNA methylation—DNA methylation was quantified in bisulfite 
converted genomic DNA from whole blood, using the Illumina Infinium 
HumanMethylation450 array in all samples. Cohort specific methods are summarised in 
Supplementary Information Table 2. DNA methylation was quantified on a scale of 0-1, 
where 1 represents 100% methylation. Preprocessing and quality control criteria are 
summarised in Supplementary Information Table 2.
The association of DNA methylation with body mass index (BMI, a measure of adiposity) 
was tested in each cohort separately by linear regression using an established analytic 
strategy to reduce batch and other technical confounding effects in quantification of DNA 
methylation, and to take account of the potential confounding effects arising from cryptic 
alterations in the white cell composition of blood. Briefly, in the LOLIPOP and KORA 
studies, raw signal intensities were retrieved using the function readIDAT of the R package 
minfi, version 1.6.0, from the Bioconductor open source software (http://
www.bioconductor.org/), followed by background correction with the function 
bgcorrect.illumina from the same R package. Detection P values were derived using the 
function detectionP as the probability of the total signal (methylation + unmethylated) being 
detected above the background signal level, as estimated from negative control probes. 
Signals with detection P values ≥ 0.01 were removed. Similarly, signals summarized from 
less than three functional beads on the chip were removed. Observations with less than 95% 
CpG sites providing a signal were subsequently excluded from the data set. To reduce non-
biological variability between observations, data were quantile normalized with the function 
normalizeQuantiles of the R package limma, version 2.12.0, from Bioconductor, separately 
in six probe categories based on probe type and colour channel. If not stated otherwise, this 
preprocessing pipeline was used for all data used in downstream analyses.
In order to account for technical effects during the experiment, we performed principal 
component analysis (PCA) on the signal intensities for the 235 positive control probes on the 
450k array, which assess multiple steps in the laboratory processing. The resulting principal 
components (PCs) are thought to capture technical variability in the experiment and the first 
20 control probe PCs were included as covariates in the model to remove technical biases.
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To estimate proportions of white blood cell types, we used the method by Houseman et al.22 
They provide 500 CpG sites showing the most pronounced cell type specific methylation 
levels in an experiment based on purified cells. Of these, 473 CpGs were available on the 
450k array. Following the proposed procedure and using the R code provided with the 
manuscript (R function projectWBC), we used these 473 CpG sites to infer white blood cell 
proportions (i.e., proportion of granulocytes, monocytes, B cells, CD4+ T cells, CD8+ T 
cells and natural killer cells) in our samples. These proportions were subsequently used as 
covariates in the model to avoid cell type confounding.
Epigenome-wide association—We performed single marker tests separately in each 
cohort using linear regression to examine the association of each autosomal CpG site with 
BMI; association results are presented, as the change in BMI per unit change in methylation 
(0-1 scale, corresponding to 0-100% change in methylation). We adjusted for age, gender, 
smoking status, physical activity index and alcohol consumption, as well as for the first 20 
control probe PCs and for the estimated white blood cell proportions; this set of covariates is 
henceforth referred to as “discovery covariates”. We corrected the association results for the 
genomic control inflation factor (GCin), in order to account for population stratification and 
other forms of cryptic structure in the data, which can for instance arise from unobserved 
confounding. Markers on the sex chromosomes were tested similarly for association with 
BMI, but separately in men and women. Results were combined across cohorts by inverse 
variance meta-analysis using METAL version 2011-03-25 (http://www.sph.umich.edu/csg/
abecasis/Metal/). The resulting P values where then corrected for in a second round of 
genomic control (GCout). There were 466,186 autosomal markers for analysis after quality 
control. We set the threshold for epigenome-wide significance as P<1x10-7, to provide a 
conservative Bonferroni correction for the number of markers tested.23 As additional 
analyses we also investigated the relationship between BMI and DNA methylation amongst 
the 11,233 X-chromosomal and 417 Y-chromosomal CpG sites assayed. Our sample size 
(N=5,387 individuals) provides 80% power to identify a change of 8.4kg/m2 in BMI per unit 
increase in methylation (ie 0-1, where 1 is 100% methylation) at P<1.0x10-7.
To assess the stability of discovery results towards the analytic choices made, we performed 
sensitivity analyses to determine the impact of control probe PCs, methylation PCs, and 
genetic PCs as covariates. Specifically, we compared results from the discovery meta-
analysis when the first 10, 20, 30 and 40 control probe PCs were included as covariates, 10 
or 20 PCs derived from a PCA on the matrix of methylation β-values, 10 or 20 PCs derived 
from a PCA on the matrix of methylation values adjusted for the discovery covariates and 
BMI, or 5 PCs derived from a PCA on SNP data were included as covariates. PCA of the 
methylation data was performed separately for each cohort based on quantile normalised 
beta-values of autosomal probes without missing data. Genetic PCs (SNP PCs) were 
generated separately for each cohort and genotyping platform (Supplementary Information 
Table 25). The correlation between SNP PCs and methylation PCs was assessed using linear 
regression (Supplementary Information Figure 9). Discovery results are very stable towards 
the considered variations in covariates, with correlations of effect sizes between the models 
varying between 0.99 and 1.0 (Supplementary Information Figures 3 and 10). In addition, 
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SNPs in the probe sequences did not materially affect the observed associations 
(Supplementary Figure 4, Supplementary Information Table 5).
Replication testing—Markers associated with BMI at P<1x10-7 in the discovery 
experiment as within ±500 kb of each other were considered as a single genetic region. At 
each locus we identified the CpG sites with lowest P value for association with BMI 
(sentinel marker). Our choice of 1Mb to define a genetic locus was made to take account of 
long-range enhancers.
At each locus we identified the sentinel marker (CpG site with lowest P value for association 
with BMI), and carried out replication testing in separate samples of whole blood from 
European and Indian Asian men and women in population-based studies (N=4,874, 
Supplementary Table 1). The 207 sentinel CpG sites were assayed using the Illumina 40K 
methylation array; cohort-specific details of analysis pipelines are described in 
Supplementary Information Table 2. Results were combined across discovery and replication 
by weighted z meta-analysis. Epigenome-wide significance was set at P<1x10-7 providing 
Bonferroni correction for the 466,186 autosomal markers tested. Our choice of threshold is 
supported by the results of permutation testing.23. Twenty of the 207 markers did not reach 
P<0.05 in replication testing. However, all 20 showed consistent direction of effect between 
discovery and replication stages (P=1.9x10-6, binomial test, Supplementary Table 3), 
suggesting that the majority are unlikely to be false positive associations.
To assess whether the 187 identified sentinel CpGs were enriched for intermediately 
methylated CpGs (sites with 20-80% average methylation), we randomly generated 100,000 
sets of 187 CpGs and determined the number of intermediately methylated CpGs for each of 
them in order to derive an expected distribution under the null hypothesis of no enrichment. 
We then compared the observed number of intermediately methylated CpGs for the 187 
sentinel CpGs against the null distribution to calculate an empirical P value.
An exact binomial test (R function binom.test) was used to test whether consist direction of 
effect between discovery and replication was observed more often than expected by chance 
amongst the 20 non-replicating CpG sites.
Replication by pyrosequencing—As a technical validation we used pyrosequencing to 
carry out replication testing of the relationship between DNA methylation and BMI at 4 loci, 
using samples of whole blood from 990 Europeans and 1,720 Indian Asians participating in 
the LOLIPOP study. Pyrosequencing was carried out using biotinylated primers to amplify 
bisulfite-treated DNA (Supplementary Information Table 26). The biotinylated PCR 
products were then immobilized on streptavidin-coated Sepharose beads (GE Healthcare, 
Orsay, France). Pyrosequencing was performed with the PyroMark Q96 MGMT kit (Qiagen, 
Courtaboeuf, France) on a PSQTM96 MA system (Biotage, Uppsala, Sweden).
Isolated white blood cell studies
Samples—30 obese (BMI>35kg/m2) and 30 normal weight (BMI<25kg/m2) individuals 
were recruited at random from the outpatient departments at Ealing and University College 
Hospitals London. All participants gave written informed consent for inclusion in the study 
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(Research ethics committee references: 07/H0712/150, 13/LO/0477, and ID#09/H0715/65). 
Obese cases and normal weight controls were matched by age (within 5 yrs), sex, and 
ethnicity.
Fluorescence activated cell sorting (FACS)—For each participant, we collected 
12mls whole blood (EDTA). Samples were processed immediately to isolate white blood 
cell subsets (monocytes, neutrophils, CD4 and CD8 lymphocytes) through: i. red blood cell 
lysis (manufacture instructions, BioLegend); ii. staining of unlysed white blood cell subsets 
(>20mins in 50mcl Ca++ free PBS with 5mM EDTA and 1% Human Albumin; 1mcl anti-
CD14 PE-Cy7 (Clone-M5E2, BD), anti-CD16 BV510 (Clone-3G8, BioLegend), anti-CD45 
BV605 (Clone-HI30, BioLegend), anti-CD8 APC (Clone-SK1, BioLegend); 2mcl anti-CD3 
PE (Clone-Leu-4, BD), anti-CD4 FITC (Clone-RPA-T4, BioLegend); iii. filtering of stained 
samples to remove clumped cells (30micron mesh, Miltenyi Biotec); and iv. staining of dead 
cells (1mcl Sytox Blue, Life Technologies).24,25
Lysed, stained samples were sorted on a FACSAria II SORP cell sorter at flow rate 6,000–
9,000 events/second. Data was collected with FACSDiva 8 and analysed with FlowJo V10. 
Fluorescence minus one negative controls were used to determine positive/negative 
boundaries for each gate in the experimental set up.{Perfetto, 2004 #248} Daily Cytometer 
Set-up and Tracking quality control beads were run to ensure alignment and 
parameterisation of the FACS (Anti-Mouse Ig κ/Negative Control, BSA; Compensation Plus 
Particles, BD). Sytox Blue (450/50V nm) negative events were considered to be live cells. 
FCS-A and SSC-A were then used to separate granulocytes from monocyte and lymphocyte 
populations. Neutrophils (CD14-, CD16+) were separated from other granulocytes. 
Monocytes were then separated from lymphocytes in a two stage process as CD14+, CD45+ 
and CD16- cells. Finally, CD4+ and CD8+ cells were separated from other lymphocytes 
based on the following staining patterns: i. CD4+ cells: CD3+, CD4+, CD8-, CD14- and 
CD45+; ii. CD8+ cells: CD3+, CD4-, CD8+, CD14- and CD45+. Sorted cell subsets were 
assessed for purity, then pelleted and snap frozen for storage at -80C. Average purities were: 
neutrophils 98.3% (SD 1.2); monocytes 99.2% (SD 0.7); CD4+ lymphocytes 99.6% (SD 
0.4); CD8+ lymphocytes 97.9% (SD 2.0).
Genomic DNA was isolated (Qiagen QIAshredder; Allprep DNA/RNA Micro) according to 
manufacture instructions. Isolated genomic DNA was quantified (Qubit double-stranded 
DNA broad range assay) then stored at -80C for genome-wide DNA methylation assays.
Quantification of DNA methylation and data processing—Genomic DNA 
(0.2-1.0mcg) underwent bisulphite conversion using EZ DNA Methylation-Direct Kit 
(Zymo Research, Irvine, CA). In brief, DNA samples underwent bisulphite conversion by 
incubation with the CT Conversion Reagent for 8 mins at 98°C, 3.5 h at 64°C, followed by 
18 h at 4°C in a thermocycler. The treated DNA was added to a Zymo-Spin IC Column, 
desulfonated using M-Desulphonation Buffer, and then eluted from the column in 12µl of 
M-Elution Buffer.
Methylation analysis of the bisulphite-treated DNA was performed using Illumina Infinium 
MethylationEPIC Beadchip (Illumina, San Diego, CA) according to standard protocol. In 
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brief, 4µl of bisulfite-treated DNA was denatured, neutralized and subjected to an overnight 
whole-genome amplification reaction. The amplified DNA was then enzymatically 
fragmented, precipitated and resuspended in hybridization buffer before being dispensed 
onto the MethylationEPIC beadchips for hybridization. After hybridization, the beadchips 
were processed through a primer-extension protocol and subsequently stained. Finally, the 
beadchips were coated and imaged using the HiScan System (Illumina).
All samples passed Quality Control and PCA showed clear separation of cell-types. 
Methylation-values for 179 (of 187) sentinel CpGs were retrieved, as described above for 
epigenome-wide association in blood, and the difference in DNA methylation between obese 
cases and normal weight controls tested using linear regression, adjusted for age, gender and 
ethnicity.
Genetic association studies
We used genetic association and the concept of Mendelian randomisation to investigate for 
potential causal relationships between DNA methylation and adiposity.{Relton, 2012 #24} 
Briefly, Mendelian Randomisation goes back to the more general instrumental variable 
concept. As an instrumental variable, it uses a genetic variant (or a combination of genetic 
variants) Z associated with a variable X in order to show causal relation between X and 
another variable Y. It relies on the fact that the alleles of a genetic variant are inherited 
randomly from parents to offspring, so that the relation of a genetic variant with a phenotype 
should not be confounded (with exceptions including population stratification). Thus, if the 
effect of X on Y is causal and the study has enough power, Z should also associate with Y. 
Specifically, the predicted association of Z with Y can be calculated as follows, assuming 
linear relationships and assuming that Z is unrelated to Y given X and unrelated to any 
unobserved confounders U:
(1) X = α1 + β1Z + γ1U, where γ1U plays the role of the error term that is per 
assumption unrelated to Z
(2) Y = α2 + β2X + γ2U = α2 + β2(α1 + β1Z + γ1U) + γ2U = α2 + β2α1 + β2β1Z + 
(β2γ1 + γ2)U = α3 + β3Z + γ3U
➔ Predicted effect of Z on Y: β3 = β2β1
Unbiased estimation and formal inference on the causal effect β1 of X on Y (where X and Y 
represent a CpG-phenotype-pair) heavily relies on strong genetic effects and typically 
requires tens of thousands of samples for adequate power.26 Since these sample sizes are 
currently not available for epigenomic datasets we instead explored consistency of the 
predicted effect of Z on Y versus the actually observed effect, thereby obtaining some 
indication on the plausibility of a causal effect of X on Y. This was done in two directions, 
studying causality of the effect of DNA methylation (X) on BMI (Y) and of BMI (X) on 
DNA methylation (Y).
DNA methylation as determinant of BMI (causal analysis)
To address the question of DNA methylation being a determinant of BMI (whereby X=DNA 
methylation, Y=BMI) we used data on genetic variants from 4,034 participants of the KORA 
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and LOLIPOP studies (Supplementary Information Table 25) to identify cis (1Mb) SNPs (Z) 
influencing methylation in blood at the 187 sentinel CpG sites. The associations between 
SNPs and methylation were tested in each data set separately using linear models with 
methylation as response and SNP as independent variable, adjusting for the discovery 
covariates, and then combined by inverse variance meta-analysis using METAL, version 
2011-03-25. Our sample size (Nmax=4,034 individuals) provides 80% power to identify a 
change in methylation of 0.5% (in absolute terms) per allele copy at P<5.0x10-8. (ie 
genome-wide significance). Results for all 173,367 pairs reaching P<5x10-8 (conventional 
genome-wide significance) are provided in Supplementary Information Table 27. We 
excluded three CpGs that shared no cis-SNPs across all data sets, and a further 9 CpGs 
because they had SNPs within their probe-binding sequence. For the remaining 175 CpG 
sites, the single SNP with the lowest P value for association with methylation was chosen as 
an instrumental variable (Supplementary Information Table 28). As mentioned above, to be 
an appropriate instrument, a SNP must not be directly associated with BMI (Y) but only 
through the respective CpG (X). For this purpose we removed six CpG-SNP pairs from the 
analysis because the corresponding SNPs remained associated with BMI after adjustment for 
the sentinel CpG (cg07136133, cg08548559, cg09152259, cg12484113, cg18120259, 
cg26403843). Statistical significance was inferred at P<2.9x10-4 (corresponding to P<0.05 
after Bonferroni correction for 175 tests).
To enable comparison with the observed effect of SNPs on BMI obtained from published 
data, we eassessed the relationship between DNA methylation and adiposity in linear 
models, using an inverse-normal transformation of BMI as the outcome variable to be 
consistent with the GIANT GWAS.12 The associations between DNA methylation and 
inverse-normal transformed BMI were quantified in LOLIPOP and KORA cohorts 
separately, followed by inverse variance meta-analysis using METAL, version 2011-03-25. 
We then calculated the predicted effect sizes and standard errors (βpred and SEpred) as 
follows:
The predicted effect sizes were compared against the observed effects of SNPs on BMI, 
whereby the latter were obtained from large published GWAS to increase power.12 
Statistical significance for individual SNPs was again inferred at P<2.9x10-4. We used 
correlation analysis to examine the global relationship between predicted and observed 
effect on BMI for the SNPs influencing DNA methylation across the sentinel CpG sites.
DNA methylation as consequence of BMI (consequential analysis)
To test the hypothesis of DNA methylation being a consequence of BMI (whereby X=BMI, 
Y=DNA methylation), we followed a similar procedure as described above for the opposite 
direction with minor differences.
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First, instead of using a single SNP as instrumental variable, we calculated a weighted 
genetic risk score (GRS) comprising SNPs reported to influence BMI.12 Again, for the GRS 
to provide a valid instrument, the included SNPs must not show direct association with the 
CpG (Y) but only through BMI (X). For this purpose we removed three SNPs (rs12444979, 
rs10968576, rs7359397) which remained significantly associated at P<8.4x10-6 
(corresponding to P<0.05 after Bonferroni correction for the 187 x 32 tests performed) with 
at least one of the sentinel CpGs after adjusting for BMI. The final GRS was calculated as 
the sum of risk allele dosage of the remaining 29 SNPs previously reported to associate with 
BMI, weighted by the reported effect sizes.12
Second, the observed effects of GRS on DNA methylation were quantified using linear 
models as described above adjusted for the discovery covariates amongst participants of the 
KORA and LOLIPOP studies. Regression analysis was carried out in the KORA and 
LOLIPOP cohorts separately and results combined by inverse variance meta-analysis using 
METAL, version 2011-03-25.
DNA methylation in blood and adiposity in prospective population studies
We used data from the KORA (N=1,435 Europeans) and LOLIPOP (N=1513 Indian Asians) 
to examine the prospective, longitudinal association between DNA methylation at baseline 
and subsequent change in BMI during follow-up. We carried out linear regression with 
change in BMI during follow-up as response variable, and technically adjusted baseline 
methylation as the predictor variable, with age, sex, physical activity, smoking, alcohol 
intake, estimated white blood cell proportions and BMI at baseline, as well as follow-up 
time as additional covariates. Data were analysed in KORA and LOLIPOP separately, 
followed by inverse variance meta-analysis using METAL, version 2011-03-25.
We studied the longitudinal relationship between change in BMI and change in DNA 
methylation amongst 1,435 participants of the KORA S4/F4 cohort with methylation data 
available both at baseline and at the 7-year follow-up timepoint. To ensure comparability of 
methylation measurements from the two time points measured in two batches, methylation 
β-values were jointly adjusted for the first 20 PCs obtained from a PCA on the positive 
control probes, and residuals were subsequently used as adjusted methylation values. Linear 
models were used with change in BMI during follow-up as response variable, and change in 
technically adjusted methylation as independent variable, including age, sex, physical 
activity, smoking, alcohol intake and estimated white blood cell proportions both at baseline 
and followup.
Adiposity and DNA methylation in other tissues
DNA methylation in adipose tissue—We investigated whether the observed 
methylation markers in blood are representative of BMI-associated methylation changes in 
adipose tissue. We used a data set of 542 adipose tissue samples from the TwinsUK study to 
test association of the 187 identified methylation markers with BMI. The association of BMI 
with methylation was quantified using a linear mixed-effects model adjusting for chip, for 
bisulfite conversion level and bisulfite conversion efficiency, smoking state (3 categories: 
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current, former and never smokers), alcohol intake (in g/d) and age, with zygosity and 
family as random effects.
We carried out sensitivity analyses to assess the potential contribution of cryptic structure 
arising from differences in cell composition of the adipose tissue samples. In the absence of 
validated approaches for imputation and adjustment for adipose tissue cell subset 
composition, and the potential limitations of published reference-free approaches for 
separation of true and confounded signal,23 we used PCA to quantify latent structure in the 
adipose tissue methylation data, and included the top 5 components as covariates in the 
regression model.
We separately compared DNA methylation between paired samples of blood and 
subcutaneous adipose tissue (available for the same N=201 individuals, TwinsUK). Blood 
methylation values were first adjusted for age, chip and chip position, smoking state, alcohol 
intake, and estimated white blood cell subsets by taking the residuals from a linear model 
with these as covariates. Similarly, adipose tissue methylation values were adjusted for age, 
chip, bisulfite conversion level, bisulfite conversion efficiency, smoking state, alcohol intake, 
and the top 5 PCs from the adipose methylation data. Pearson’s correlation was then 
determined between the adjusted methylation values.
Finally, we used genetic association to carry out causality analyses on the association 
between BMI and DNA methylation in adipose tissue, as described above for blood. We 
studied a subset of 325 adipose tissue samples from the Twins UK cohort with genotype data 
available. Regression analyses in adipose tissue between BMI, SNPs/GRS and CpGs were 
carried out using the R package lme4, and with smoking, alcohol intake, age, zygosity 
(random effect), family (random-effect), beadchip, bisulphite conversion batch and 
bisulphite conversion efficiency as covariates.
DNA methylation in isolated adipocytes—Subcutaneous adipose tissue samples were 
obtained intraoperatively in 24 morbidly obese individuals (BMI >40kg/m2) undergoing 
laparoscopic bariatric surgery and 24 healthy controls (BMI <30kg/m2) undergoing non-
bariatric laparoscopic abdominal surgery. Participants were unrelated, between 18-60 years 
of age, from a multi-ethnic background, and free from type-2 diabetes. Controls were 
matched to cases by age, sex, and ethnicity. All participants gave informed consent (Ethics 
committee reference 13/LO/0477).
Adipose samples were processed immediately to isolate populations of primary human 
adipocyte cells using established protocols.27 Polypropylene plastic ware was used to 
minimise adipocyte cell lysis. Adipose tissue samples were minced into 1-2mm3 pieces and 
washed in Hank’s buffered salt solution (HBSS), before digestion using type 1 collagenase 
(1mg/ml, Worthington) in a water bath at 37C shaking at 100rpm for ~45min. Digested 
samples were filtered through a 300 micron nylon mesh to remove debris, and the filtered 
solution centrifuged at low speed (500-g; 5min; 4 degrees), to leave four layers: top to 
bottom – (1) oil, (2) mature adipocytes, (3) supernatant, and (4) stromovascular pellet. After 
removal of the oil layer, the mature adipocyte layer was collected by pipette, washed in ~5x 
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volume of HBSS and recentrifuged. After 3 washes the adipocyte cell suspension was 
collected for snap freezing and storage at -80C.
Genomic DNA and RNA were extracted from the isolated adipocytes using the Qiagen 
AllPrep DNA/RNA/miRNA Universal Kit according to manufacturer’s protocol for lipid-
rich samples. Methylation of genomic DNA was quantified using the Illumina 
HumanMethylation450 array in a single batch according to manufacturer’s specifications. 
Raw methylation data were preprocessed using R, version 2.15. Bead intensity was retrieved 
using the R package minfi, version 1.6.0. Marker intensities were quantile normalised for 
analysis. PCA of control probe intensities was performed to quantify cryptic structure in the 
data arising from technical factors. Logistic regression was used to examine the association 
of each CpG site with morbid obesity compared to normal weight, adjusting for age, sex and 
ethnicity, and the first 5 control probe PCs.
DNA methylation in liver tissue—Liver samples were obtained percutaneously for 
patients undergoing liver biopsy for suspected NAFLD or intraoperatively for assessment of 
liver histology. Normal control samples were recruited from samples obtained for exclusion 
of liver malignancy during major oncological surgery. None of the normal control 
individuals underwent pre-operative chemotherapy and liver histology demonstrated absence 
of both cirrhosis and malignancy Study design, sampling method and data collection have 
been described in detail elsewhere.30 For methylation analysis, bisulfite conversion was 
performed using the Zymo EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA), 
and hybridization of the Illumina HumanMethylation450 array (Illumina, SanDiego, CA). 
mRNA expression analysis was performed using the HuGene 1.1 ST gene (Affymetrix, 
Santa Clara, Ca, USA) according to the manufacturers protocols. Hybridization signals were 
analyzed using GenomeStudio software (default settings; GenomeStudio ver. 2011.1, 
Methylation Analysis Module ver. 1.9.0; Illumina Inc) and internal controls for 
normalization.
Cross-tissue methylation—For extended cross-tissue correlation analyses, publicly 
available data (GSE48472) were downloaded from the Gene Expression Omnibus (GEO) 
database.9 Briefly, the dataset consists of 41 samples from six individuals of blood, liver, 
muscle, pancreas, subcutaneous fat, omentum and spleen analysed on the 450K methylation 
array. Data from the 187 CpG sites of interest were extracted and plotted using the heatmap.
2 function in the R package gplots (version 2.17.0). Mean methylation levels for each CpG 
site across all samples within each tissue type were used to test for pairwise correlation 
between tissue types.
Functional genomics
Genomic annotation analyses—To test for functional enrichment of the 187 CpG sites 
associated with BMI, we used annotations of genomic context provided by Illumina, and of 
histone modification ChIP peaks (H3K4me1, H3K4me3 and H3K27Ac, marks of open 
chromatin) and DNaseI Hypersensitivity Sites in 127 different cell types in the Roadmap and 
ENCODE (Release 9, UCSC) datasets. We mapped each probe on the Illumina 450k array 
background to the annotation categories and recorded overlap at each probe as a binary 
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variable. To determine whether enrichment occurred more often than expected by chance, 
we generated 10,000 sets of 187 CpGs, each matched with the BMI sentinel CpGs for 
methylation mean (±2%) and standard deviation (±0.2%), but otherwise selected at random. 
For each epigenetic mark, we then calculated the number of overlapping sites amongst the 
187 replicating markers (observed) and 10,000 permuted sets of 187 markers (expected). We 
calculated the fold enrichment as observed/mean(expected) and obtained an empirical P 
value from the distribution of expected.
Gene expression studies—Transcriptome-wide measurements of gene expression in 
blood along with measurements of DNA methylation from the same blood sample were 
available for participants of both the KORA F4 (N=703) and LOLIPOP (N=1,082, 907 
Indian Asians, 175 Europeans) studies (Supplementary Information Table 15). KORA 
samples were analysed with the Illumina HumanHT-12 v3 BeadChip array. Blood sample 
collection and RNA isolation and preparation have been described in detail.28,29 Gene 
expression data were quantile normalized and log2 transformed using the R package lumi, 
version 2.8.0, from Bioconductor in R, version 2.14.2. In LOLIPOP, gene expression 
analysis was performed with the Illumina HumanHT-12 v4 BeadChip array according to 
manufacturer's protocol. Background correction (using negative controls), quantile 
normalisation and log2 transformation was performed using the R-package limma (function 
neqc).
To examine associations of DNA methylation with gene expression we carried out linear 
regression with log2 transformed gene expression as the response variable and methylation 
βvalues as independent variable. In KORA, the model was adjusted for the discovery 
covariates and technical covariates related to the expression measurement (RNA integrity 
number, RNA amplification plate, sample storage time). In LOLIPOP, the model was 
adjusted for age, sex, methylation control probe PCs and technical covariates related to the 
expression measurement (RNA integrity number, RNA extraction batch, RNA conversion 
batch, scanning batch, array and array position). Results were analysed in KORA, LOLIPOP 
Indian Asians and LOLIPOP Europeans separately, then combined by inverse-variance 
meta-analysis using METAL (version 2011-03.25). Statistical significance was inferred at 
P<9.0x10-6 (i.e. P<0.05 after Bonferroni correction for 5,551 CpG-expression pairs).
To assess whether the 187 sentinel CpGs were enriched for association with gene 
expression, we used the same testing concept as described above based on constructing a 
null distribution from 10,000 randomly selected matched sets of 187 CpGs. For each 
permuted set we determined the number of significantly associated expression probes in cis 
(P<9.0x10-6) as described above and compare the resulting distribution with the observed 
number of gene expression associations for the 187 sentinel CpG sites to calculate an 
empirical P value.
Finally, we examined the association between DNA methylation and gene expression in 
TwinsUK adipose tissue samples (N=499) for the 44 methylation-expression pairs that were 
significant in blood. Expression values were adjusted for age and chip using a linear model. 
The association of methylation and expression was then determined in linear mixed-effects 
models with adjusted expression as response and methylation as the independent variable, 
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adjusting for age, chip, bisulfite conversion level and bisulfite conversion efficiency, with 
zygosity and family as random effects. After QC filtering of methylation and expression 
data, results were available for 36 methylation-expression pairs.
Candidate genes and gene-set enrichment analyses—The standard Illumina 
annotation does not identify a gene for all CpG sites on the 450K microarray. We therefore 
identified candidate genes based on the following criteria: i. Proximity: gene nearest to the 
CpG site (N=187 genes) and ii. Gene expression: all local genes (up to ±500 kb) with 
expression associated with the marker at P<0.05 after Bonferroni correction for 5,551 tests 
(N=38 genes). This resulted in a list of 210 unique genes (Supplementary Information Table 
19).
Gene annotations were downloaded from ensembl (grch37.ensembl.org) using R package 
biomaRt, version 2.18.0, from Bioconductor, and overlapped with the cg positions as 
annotated in the Illumina annotation using the R package GenomicRanges, version 1.14.4, 
from Bioconductor. We downloaded curated pathway information (c2.all.v5.0.symbols.gmt) 
from the GSEA MSigDB platform (http://www.broadinstitute.org/gsea/msigdb), resulting in 
1,135 pathways, to investigate enrichment of the set of candidate genes against curated 
pathway sets (BIOCARTA, KEGG, REACTOME). An enrichment P value was calculated 
empirically based on permutation testing, using the Benjamini-Hochberg (false-discovery-
rate) procedure. As a sensitivity analysis the gene-set enrichment analysis was repeated 
using the genes annotated by Illumina, and using more permissive proximity criteria 
(Supplementary Information Table 29). Results become less statistically significant when 
candidate gene selection based on proximity alone was extended to include all genes over 
distances up to 500kb.
Clinical implications
DNA methylation and metabolic traits—We investigated the association between the 
187 sentinel methylation markers and metabolic disturbances associated with adiposity 
amongst participants of the KORA (N=1,697) and LOLIPOP (N=2,462) studies with 
available measurements of the following BMI-related clinical traits: LDL cholesterol, HDL 
cholesterol, total cholesterol, fasting triglycerides, fasting glucose, fasting insulin, HbA1c, 
systolic and diastolic blood pressure, C-reactive protein, weight, height and waist-hip ratio. 
Linear models were used with trait as response and methylation as independent variable, 
adjusting for the discovery covariates. Results from KORA and LOLIPOP studies were 
analysed separately, then combined by inverse variance meta-analysis using METAL, 
version 2011-03-25. Associations were considered significant at P<2.1x10-5 (corresponding 
to P<0.05 after Bonferroni correction for 187 x 13 tests).
To investigate potential causal relationships between the methylation markers and BMI-
related clinical traits, we performed causality analyses as described above for the primary 
phenotype (BMI). For each clinical trait, GWAS datasets of the most comprehensive meta-
analyses published to date with access to genome-wide association results were retrieved 
(Supplementary Information Table 30), to provide SNPs influencing trait. SNPs associated 
with multiple traits were assigned to the most strongly associated trait (lowest P value). 
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Clinical traits were transformed as described in the respective GWAS. Genetic risk scores 
were calculated as described above for BMI, after removal of SNPs with direct genomic 
effects (SNPs that remain associated with the sentinel CpG after adjustment for the trait). 
Regression analyses were carried out in the KORA F4 and LOLIPOP cohorts separately and 
results were combined by inverse variance meta-analysis using METAL, version 
2011-03-25.
Association with incident T2D—We tested the association of DNA methylation at the 
187 identified CpG sites with incident T2D amongst participants of the LOLIPOP study. All 
participants (N=2,664) were free from T2D at the time of measurement of DNA 
methylation; incident T2D (N=1,074) was defined as either new physician diagnosis, or 
HbA1c≥6.5%. Associations with T2D were evaluated by logistic regression adjusted for the 
discovery covariates. We initially tested the association in single marker tests, then in a fully 
saturated model comprising all 187 markers to identify independent effects.
To combine information across loci, we calculated a weighted methylation risk score (MRS) 
as the sum of the standardised methylation values at each marker that reached nominal 
significance (P<0.05) in the fully saturated multivariate model, weighted by marker-specific 
effect size. We then tested the association of the MRS with incident T2D using logistic 
regression, before and after adjustment for traditional T2D risk factors (BMI, WHR, 
glucose, HbA1c).
Replication testing of the association of MRS with T2D was carried out in a nested case-
control study within the KORA S3/S4 comprising 200 subjects with newly diagnosed T2D 
and 200 control matched for age (±2 years), sex, cohort and observation time until diagnosis 
of diabetes. Data were analysed using conditional logistic regression using the function 
clogit of the R package survival, version 2.37.4.
Software
Unless stated otherwise, all calculations were performed using R, version 3.0.1. For all 
meta-analyses, METAL, version 2011-03-25, was used. Custom R code for the respective 
analyses is available at: http://metabolomics.helmholtz-muenchen.de/bmi_methylation/.
Availability of data
Summary statistics from the epigenome-wide association study can be accessed from the 
European Genome-Phenome Archive (accession number: EGAS00001001922). KORA 
methylation data are available upon request through the application tool KORA.PASST 
(http:/epi.helmholtz-muenchen.de); LOLIPOP data are available from the Gene Expression 
Omnibus (Ref: GSE55763); EPICOR data are deposited in the HuGeF repository (http://
www.hugef-torino.org) and are available on request.
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Extended Data
Extended Data Figure 1. Study design.
Epigenome-wide association and replication testing was performed in order to identify 
methylation sites associated with adiposity. In the discovery step, four large cohorts were 
included with Illumina 450k DNA methylation data available, which were preprocessed and 
quality controlled according to a harmonized protocol. Epigenome-wide association was 
performed in every single study with BMI as response variable and methylation β-value as 
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independent variable, adjusting for covariates as described in the Online Methods. At a 
genome-wide significance level of P<1x10-7, 278 methylation sites from 207 regions were 
identified. In the replication step, 187 of these replicated in independent samples. Genetic 
association and causality analyses were used in order to investigate whether the identified 
methylation signals underlie the development of adiposity or are the consequence of 
adiposity. The findings were supported with the help of longitudinal analyses. The cross-
tissue analyses represent a first step towards extending our observations in blood to 
metabolically relevant tissues. The functional genomics and gene expression analyses help 
to link the observed methylation associations to transcriptional outcomes, while the gene-set 
enrichment analysis provides a way to summarize the potentially affected metabolic 
pathways. Finally, we study the relationships of methylation to adiposity related metabolic 
traits and type 2 diabetes to address the clinical relevance of our findings.
Extended Data Figure 2. 
Distribution of methylation values at the 187 sentinel CpG sites compared to the ~473K 
CpG sites assayed by the Illumina Infinium 450K Human Methylation array. The 187 
identified methylation-BMI associations are strongly enriched for CpG sites with 
intermediate levels of methylation, consistent with the presence of epigenetic heterogeneity 
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at these loci in blood (157/187 sites with 20-80% methylation, a 3.0-fold enrichment 
compared to microarray background, P=1.4x10-22 Fisher’s test).
Extended Data Figure 3. 
DNA methylation at the sentinel CpG sites in whole blood and in 4 isolated cell subsets 
(Monocytes, Neutrophils, CD4+, CD8+) from 60 individuals (30 obese cases, and 30 normal 
weight controls) by Illumina MethylationEPIC array, which quantifies 179 of the 187 
sentinel markers. Results are shown as a heatmap, coded by methylation value 
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(hypomethylation <0.2; intermediate methylation 0.2-0.8, hypermethylation >0.8). Results 
show the presence of intermediate methylation (and hence epigenetic heterogeneity) at the 
majority of loci, and in the majority of cell types, in both cases and controls.
Extended Data Figure 4. 
Association of DNA methylation with obesity in the 4 cell subsets studied, based on 
quantification of methylation at 179 of the sentinel methylation markers amongst 30 obese 
cases and 30 normal weight controls. Results are presented as QQ plots of the observed 
association test statistics in each of the isolated cell subsets.
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Extended Data Figure 5. 
Comparison of effect sizes between isolated white cell subsets. Results are presented as the 
difference in methylation between obese cases and normal weight controls (Methylation in 
cases – methylation in controls, in absolute terms on % scale) in the respective isolated 
white cell subset (y axis) compared to the average case-control difference across all 4 cell 
subsets studied (x axis).
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Extended Data Figure 6. 
Mean methylation levels at the 187 sentinel methylation markers associated with BMI, 
across 7 tissue types (blood: N=6; liver: N=5, muscle: N=6, omentum: N=6, pancreas: N=4, 
subcutaneous (SC) fat: N=6, spleen: N=3). The lower panel displays pairwise scatterplots 
(trendline in red), while the upper panel shows the Pearson correlation coefficient and P 
values.
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Extended Data Figure 7. 
Causality analysis in adipose tissue to investigate the potential relationships between BMI 
and DNA methylation. Left panel: Causality analysis in adipose tissue investigating whether 
DNA methylation at sentinel CpG sites influences BMI. Units are change in BMI per copy 
of effect allele. For each sentinel CpG site we determined i. the effect of a previously 
identified cis-SNP on BMI predicted via methylation (x-axis), ii. the directly observed effect 
of SNP on BMI (y-axis). No CpG passed multiple testing correction for all three 
comparisons. Overall there was little relationship between the effects of SNPs on BMI 
predicted via methylation and the directly observed effect (R=-0.04 P=0.58). Right panel: 
Causality analysis in adipose tissue investigating whether DNA methylation at sentinel CpG 
sites is the consequence of BMI. Units are change in methylation per unit change in 
weighted genetic risk score (GRS). We identified SNPs reported to influence BMI in GWAS 
meta-analysis, and calculated a weighted GRS. For each sentinel CpG site we then 
determined i. the effect of GRS on methylation predicted via BMI (x-axis) and ii. the 
directly observed effect of GRS on methylation (y-axis). No CpG passed multiple testing 
correction for all three comparisons. The overall correlation between observed and predicted 
effects (R=0.73; P=1.6 x 10-32) replicates our findings in blood that methylation at the 
majority of CpG-sites is consequential to BMI.
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Extended Data Figure 8. 
The 187 sentinel CpGs are enriched for association with gene-expression in cis in blood. To 
derive an expectation under the null-hypothesis we generated 10,000 sets of matched CpGs 
(matched for mean methylation and for SD of methylation, see Online Methods), and tested 
their association with expression of A) the nearest gene, B) the gene allocated to the CpG by 
the Illumina annotation, C) all genes within a 500 kb distance and D) all genes within a 500 
kb distance excluding the nearest gene. We observe significantly more expression-probes 
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associated with the sentinel markers (red arrow) in blood compared to the 10,000 permuted 
sets (green bars).
Extended Data Figure 9. Summary statistics for the causality analyses investigating the 
relationship between DNA methylation in blood and metabolic disturbances.
Panel A. DNA methylation in blood as a potential determinant of the metabolic disturbances 
associated with adiposity (causal analysis). For each of the sentinel CpG sites we identified 
the cis-SNP (1Mb) most closely associated with DNA methylation levels. For each of the 
SNPs we then determined i. the effect of SNP on phenotype predicted via methylation, ii. the 
directly observed effect of SNP on phenotype. Results are presented as the R2 between 
phenotype specific observed and predicted effects across the 187 CpG sites, calculated using 
linear regression.
Panel B. DNA methylation in blood as a potential consequence of the metabolic 
disturbances associated with adiposity (consequential analysis). We identified the SNPs 
reported to influence each phenotypic trait (using the most recent GWAS meta-analysis, 
Supplementary Table 24), and calculated phenotype specific weighted genetic risk scores 
(GRS). For each of the CpG sites, and each of the phenotypes, we then determined i. the 
effect of GRS on methylation predicted via phenotype, with ii. the directly observed effect 
of GRS on methylation. Results are presented as the R2 between phenotype specific 
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observed and predicted effects across the 187 CpG sites, calculated using linear regression. P 
values are shown for correlations between observed and predicted effects that reach P<0.05.
Extended Data Figure 10. 
Association of established and emergent biomarkers with T2D. Results are presented as risk 
of T2D associated with the specified biomarkers in three models: i. Model 1 – adjusted for 
age and sex; ii. Model 2 – as for Model 1, but additionally for body mass index and impaired 
fasting glucose; iii. Model 3 – as for Model 2, but additionally for central obesity and insulin 
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concentrations. CRP: C-reactive protein; MRS: methylation risk score. Results for 
quantitative traits (amino acids, CRP, insulin, MRS) are presented as risk of T2D in Q4 
compared to Q1.
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Figure 1. 
Circos plot of the epigenome-wide association of DNA methylation in blood with BMI. 
Results are presented as CpG specific association test results [-log10(P)] ordered by 
genomic position. Green and blue symbols: CpG sites at loci reaching epigenome wide 
significance (P<1x10-7); grey symbols: CpG sites at loci not reaching epigenome-wide 
significance. Chromosome numbers are shown on the inner ring. Tick marks on the outer 
ring identify the genomic loci reaching epigenome-wide significance. The genes nearest to 
the sentinel methylation markers at each of the 187 loci are listed around the circos plot.
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Figure 2. 
Genetic association studies to investigate the potential relationships between BMI and DNA 
methylation in blood. 2A. Causal analysis shows results for a causality analysis 
investigating whether DNA methylation in blood at the sentinel CpG sites influences BMI. 
Units are change in BMI per copy of effect allele. For each sentinel CpG site we identified 
the cis-SNP (1Mb) most closely associated with DNA methylation levels. For each SNP we 
then determined i. the effect of SNP on BMI predicted via methylation (x-axis), ii. the 
directly observed effect of SNP on BMI (y-axis). Grey points represent CpGs not 
significantly associated with a SNP; blue points represent CpGs significantly associated with 
a SNP. For a single CpG (NFATC2IP) the associated SNP is also associated with BMI and 
95% confidence interval error bars are shown. At the other loci there was little relationship 
between the effects of the SNPs on BMI predicted via methylation and that directly observed 
(R2=0.00, P=0.86). 2B. Consequential analysis shows results for a causality analysis 
investigating whether DNA methylation in blood at the sentinel CpG sites is the 
consequence of BMI. Units are change in methylation per unit change in weighted genetic 
risk score (GRS). We identified the SNPs reported to influence BMI in GWAS meta-
analysis,12 and calculated a weighted GRS (see Online Methods). For each sentinel CpG 
site we then determined i. the effect of GRS on methylation predicted via BMI (x-axis) and 
ii. the directly observed effect of GRS on CpG (y-axis). Three CpGs (ABCG1, KLHL18, 
FTH1P20) are associated with the GRS at P<2.7x10-4 (P<0.05 after Bonferroni correction 
for 187 tests; 95% confidence interval error-bars shown). The overall correlation between 
observed and predicted effects (R2=0.81; P=4.7 x 10-44) suggests that methylation in blood 
at the majority of CpG-sites is consequential to BMI.
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Figure 3. 
Relationship between DNA methylation in blood and BMI amongst 1,435 participants of the 
KORA S4/F4 population cohort. Cross-sectional results (x-axis) are for the relationship 
between methylation in blood and BMI at each of the 187 sentinel CpG sites in the baseline 
samples; longitudinal results are for the relationship between change in methylation (in 
blood) and change in BMI after 7 year follow-up. Units for both axes are kg/m2 change in 
BMI per unit increase in methylation (scale 0-1, where 1 represents 100% methylation).
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Figure 4. 
Relative risk of incident T2D by quartile of Methylation Risk Score amongst 
normoglycaemic Indian Asians (HbA1c<6% and fasting glucose<6mmol/l) with normal 
weight (BMI 18.5-24.9kg/m2), overweight (BMI 25.0-29.9kg/m2) and obese (BMI 
≥30.0kg/m2). The P value is for the interaction between adiposity and DNA methylation on 
risk of T2D.
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